Physician profile
Douglas E Lewis
NPI 1538166996
$96,806.38
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $29K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $33,758.36 | 2019 | |
| Allergan, INC. | $21,489.43 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $20,715.80 | 2019-2020 | |
| Amgen INC. | $10,600.45 | 2019-2020 | |
| Genentech USA, INC. | $6,733.09 | 2019 | |
| Abbott Laboratories | $1,402.10 | 2019 | |
| Neurocrine Biosciences, INC. | $438.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $310.34 | 2019-2020 | |
| Emd Serono, INC. | $269.88 | 2019 | |
| Mdd US Operations, LLC | $185.50 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $176.31 | 2019 | |
| Supernus Pharmaceuticals, INC. | $166.52 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.59 | 2019 | |
| Livanova USA, INC. | $106.76 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $49.00 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $39.93 | 2019 | |
| Ucb, INC. | $31.50 | 2019 | |
| Sunovion Pharmaceuticals INC. | $29.17 | 2019 | |
| Alexion Pharmaceuticals, INC. | $28.49 | 2019-2020 | |
| Acorda Therapeutics, INC | $28.02 | 2019 | |
| Abbvie INC. | $21.87 | 2020 | |
| Promius Pharma LLC | $16.99 | 2019 | |
| Grifols USA, LLC | $16.29 | 2019 | |
| Biogen, INC. | $14.34 | 2020 | |
| Incyte Corporation | $12.80 | 2019 | |
| Pfizer INC. | $11.76 | 2019 | |
| Sk Life Science, INC. | $11.29 | 2020 | |
| Amneal Pharmaceuticals LLC | $11.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.